Glycoengineering of chimeric antigen receptor (CAR) T-cells to enforce E-selectin binding
Open Access
- 1 November 2019
- journal article
- research article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 294 (48) , 18465-18474
Abstract
No abstract availableKeywords
Funding Information
- HHS | NIH | National Heart, Lung, and Blood Institute (PO1-HL107146)
- Team Jobie Fund
This publication has 31 references indexed in Scilit:
- Targeting the EGFR signaling pathway in cancer therapyExpert Opinion on Therapeutic Targets, 2012
- Enforced hematopoietic cell E- and L-selectin ligand (HCELL) expression primes transendothelial migration of human mesenchymal stem cellsProceedings of the National Academy of Sciences, 2011
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Glycosyltransferase‐programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migrationImmunological Reviews, 2009
- Ex vivo glycan engineering of CD44 programs human multipotent mesenchymal stromal cell trafficking to boneNature Medicine, 2008
- G-CSF induces E-selectin ligand expression on human myeloid cellsNature Medicine, 2006
- Molecular Determinants of the Response of Glioblastomas to EGFR Kinase InhibitorsNew England Journal of Medicine, 2005
- Shear stress and the endotheliumKidney International, 1998
- Interleukin-1β Induces Tissue- and Cell Type–Specific Expression of Adhesion Molecules In VivoArteriosclerosis, Thrombosis, and Vascular Biology, 1998
- The fucosyltransferase FucT-VII regulates E-selectin ligand synthesis in human T cells.Journal of Cell Biology, 1996